New York State Common Retirement Fund Sells 14,500 Shares of Certara, Inc. (NASDAQ:CERT)

New York State Common Retirement Fund lowered its stake in shares of Certara, Inc. (NASDAQ:CERT) by 23.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,761 shares of the company’s stock after selling 14,500 shares during the quarter. New York State Common Retirement Fund’s holdings in Certara were worth $463,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock worth $132,455,000 after purchasing an additional 38,068 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its position in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after acquiring an additional 3,861,674 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Certara by 4.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock worth $43,494,000 after acquiring an additional 182,042 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock worth $40,668,000 after buying an additional 1,487,998 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its position in shares of Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock worth $40,253,000 after buying an additional 3,387,590 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

NASDAQ:CERT opened at $11.09 on Friday. The company has a market capitalization of $1.80 billion, a P/E ratio of -554.50 and a beta of 1.43. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $16.18. The stock’s fifty day moving average is $11.17 and its two-hundred day moving average is $11.85.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Equities analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on CERT shares. KeyCorp lowered their target price on Certara from $18.00 to $15.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Tuesday, May 6th. Morgan Stanley assumed coverage on Certara in a report on Thursday, July 3rd. They set an “equal weight” rating and a $16.00 price target for the company. Robert W. Baird boosted their price objective on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Finally, Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.29.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.